glp 1 prostate cancer May Patients Receiving GLP-1 Agonists Be at Lower Risk of Aggressiveness and Progression? Frontiers | GLP-1 Receptor Agonists:

In summary, there is a considerable number of clinical studies reporting the potential benefit of GLP-1RAs for use in cognitive disorders, including dementias and Parkinsons disease, although the majority are observational and can only suggest association

Clinical pharmacology studies show tirzepatide has a half-life of approximately 5 days, allowing for once-weekly dosing with sustained therapeutic effects (Frias et al., Diabetes Care, 2021)

doi: 10.1038/srep42394 76 ZhangYLiuLJinLYiXDangEYangYet al

The evidence base for their use in weight management remains very limited, and their use falls outside the scope of standard NHS prescribing